Given the proposed involvement of C5a in classical inflammatory diseases such as rheumatoid arthritis, [6] and a widening of the pathogenic roles of C5a to traditionally, non-inflammatory diseases such as cancer [7], and brain diseases [8], there has been a burgeoning interest in developing inhibitors of C5a for clinical use [9]. This evidence concerns the gene C5 and cancer.